• Adlai Nortye expanded its Scientific Advisory Board with the appointments of medical oncologists David S. Hong and Piro Lito.
• Hong serves as Deputy Chair in Investigational Cancer Therapeutics at UT MD Anderson Cancer Center, focused on translational and early-stage clinical development.
• Lito is Director of Basic and Translational Research in Solid Tumor Oncology at Memorial Sloan Kettering, known for research underpinning KRAS G12C inhibitor development.
• The additions support clinical development priorities for the group’s RAS inhibitor pipeline, including AN9025 and AN4035, alongside immuno-oncology candidate AN8025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Ltd. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.